文献速递脊柱关节炎

生物制剂DMARD类别影响银屑病向银屑病关节炎进展:真实世界队列研究

Biologic DMARD class influences progression from psoriasis to PsA: a real-world cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该回顾性研究纳入393例接受生物制剂DMARD治疗至少6个月的银屑病患者,随访至银屑病关节炎诊断。随访期间86例(22%)发生银屑病关节炎。在单类别暴露分析中,TNF抑制剂治疗者银屑病关节炎发生率高于IL-17、IL-23或IL-12/23抑制剂治疗者,调整后非TNF抑制剂与显著更低的银屑病关节炎风险相关。

要点

  • 非TNF抑制剂生物制剂较TNF抑制剂与更低的银屑病关节炎发生风险相关。
  • 按最长使用类别分组分析得到相似结果。
  • 按首次生物制剂分析时,各类别间银屑病关节炎患病率和调整风险无差异。

核心结论

  • 在长期真实世界银屑病队列中,非TNF抑制剂生物制剂(尤其是IL-17和IL-23抑制剂)较TNF抑制剂与更低的银屑病关节炎发生风险相关。

研究设计与样本

  • 两所大学皮肤-风湿中心的回顾性研究,纳入2008至2025年间连续接受生物制剂DMARD治疗≥6个月的成人银屑病患者,随访至银屑病关节炎诊断、末次 visit 或研究结束。

主要发现

  • 393例患者中86例(22%)随访期间发生银屑病关节炎。
  • 单类别生物制剂暴露分析(n=257)中,TNF抑制剂治疗者银屑病关节炎发生频率高于IL-17、IL-23或IL-12/23抑制剂治疗者。
  • 调整后,所有非TNF抑制剂生物制剂较TNF抑制剂与显著更低的银屑病关节炎 odds(OR范围0.16-0.25)和 hazards(HR范围0.17-0.30)相关。
  • 按最长使用生物制剂类别分组分析观察到相似结果。
  • 按首次接受生物制剂分析(n=137)时,各类别间银屑病关节炎患病率和调整 hazards 无差异。

关键数值与推荐

  • 单类别暴露分析样本量 n=257;首次生物制剂分析样本量 n=137。
  • 非TNF抑制剂 vs TNF抑制剂的调整 OR 范围 0.16-0.25,调整 HR 范围 0.17-0.30。

临床怎么用

  • 对于银屑病患者选择生物制剂时,可考虑非TNF抑制剂(尤其是IL-17和IL-23抑制剂)可能有助于降低银屑病关节炎发生风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate whether the risk of progression from psoriasis to PsA is affected by the class of bDMARD used for treatment of psoriasis, in a real-world cohort with a large follow-up. METHODS: We conducted a retrospective study in two university dermatology-rheumatology centers. Consecutive adults with psoriasis receiving bDMARDs for ≥6 months between 2008 and 2025 were included. Patients were followed until PsA diagnosis, last visit, or study end. The primary outcome was incidence of PsA. RESULTS: Among 393 patients, 86 (22%) developed PsA during follow-up. In the single-class bDMARD exposure analysis (n = 257), PsA occurred more frequently in patients treated with TNF inhibitors (TNFi) than in those receiving IL-17, IL-23, or IL-12/23 inhibitors. After adjustments, all non-TNFi bDMARDs were associated with significantly lower odds (OR range 0.16-0.25) and hazards (HR range 0.17-0.30) of PsA compared with TNFi. Similar findings were observed when patients were grouped according to the bDMARD class used for the longest duration. In patients analysed by first bDMARD received (n = 137), PsA prevalence and adjusted hazards did not differ between bDMARD classes. CONCLUSION: In this long-term real-life cohort of patients with psoriasis, treatment with non-TNFi bDMARDs-particularly IL-17 and IL-23 inhibitors-was associated with lower risk of incident PsA compared with TNFi. These findings support PsA interception and warrant prospective studies to determine whether biologic class selection can modify disease progression.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Kougkas N, Sotiriou E, Deligeorgakis D, et al. Biologic DMARD class influences progression from psoriasis to PsA: a real-world cohort study. Rheumatology (Oxford). 2026. PMID: 42584086. doi:10.1093/rheumatology/keag410

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。